… of these patients eventually develop local recurrences or … remains the primary drug used for treating advanced STS, yet … treatment with PLD+IFO, such as those with a gastrointestinal stromal tumor, … PLD (Duomeisu®, CSPC Ouyi Pharmaceutical Co. Ltd.) and …

… (Imfinzi) for the treatment of patients with resectable, … clinical paradigm.” MATTERHORN Trial Design The global, randomized … gastrointestinal stromal tumor; current or prior use of immunosuppressive medication within … any of the respective drugs; or a history …

… drug is currently in Phase I stage of clinical trial evaluation to treat Gastrointestinal Stromal Tumors … the future of Gastrointestinal Stromal Tumors Treatment. Learn about new drugs, pipeline developments, and key companies …

Panelists discuss how patient adherence to kinase inhibitors is crucial for disease control, requiring proactive adverse effect management, careful radiological monitoring, and strategies such as dose escalation to maximize treatment duration and …

… company focused on developing precision therapies for … in the SUMMIT trial, demonstrating clinically meaningful … reported on bezuclastinib treatment were hair color change … patients with imatinib-resistant gastrointestinal stromal tumors (GIST). Announce top …

Video content above is prompted by the following: Understanding GIST mutational patterns is fundamental for personalized treatment approaches in GIST care. Approximately 85% to 90% of GISTs are driven by gain-of-function mutations in KIT or PDGFR genes, …

Video content above is prompted by the following: This OncLive Peer Exchange brings together leading sarcoma specialists to discuss cutting-edge GIST treatment strategies. The expert panel features Dr Shreyaskumar Patel, Dr Richard Riedel, Dr Priscilla …

… focus on developing treatments that improve both safety and usability. Orphan drug designation … , gastrointestinal stromal tumors and additional indications. Jylamvo was initially approved by the FDA in …

… glioma and their pharmacists and caregivers had … oral suspension developed for the treatment of patients … the treatment of patients with ALL, chronic myeloid leukemia, gastrointestinal stromal tumors, … FDA orphan drug designation for SH-110 to treat …

… cancer drug approved in May 2025. Treating … Gastrointestinal Stromal Tumors (GIST) * Dermatofibrosarcoma Protuberans (DFSP), a rare type of skin cancer Developed … at the Royal Initiative Pharmaceutical … to life-saving treatment for cancer patients …